soul trial oral semaglutide cardiovascular outcomes 2024 results nejm

soul trial oral semaglutide cardiovascular outcomes 2024 results nejm Editorial Fellow Harleen Marwah, MD, summarizes the trial. Read the full at NEJM.org (link in bio). ⁣ ⁣ #ACC25 #Cardiology #ClinicalTrials #NEJM soul trial oral semaglutide cardiovascular

Name: soul trial oral semaglutide cardiovascular outcomes 2024 results nejm Editorial Fellow Harleen Marwah, MD, summarizes the trial. Read the full at NEJM.org (link in bio). ⁣ ⁣ #ACC25 #Cardiology #ClinicalTrials #NEJM soul trial oral semaglutide cardiovascular
Brand: actil.am
SKU: 25179454855
Price: 21.32 USD
Availability: InStock
Rating: 4.2619 (13 reviews)

SKU: 25179454855

4.3

USD21.32 USD48.32

Pay in 4 interest-free payments of $5.33 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 30 - Sep 4

Description

As of June 2026, survodutide is investigational and is not FDA-approved for any human use

Nothing seemed to help

UNICEF highlights that over 340 million children and adolescents aged 519 are overweight or obese, while chronic disease burden continues rising globally, encouraging development of improved long-acting and patient-friendly drug formulations to enhance treatment adherence and long-term outcomes